Once-weekly CagriSema—a combination of semaglutide and cagrilintide—has demonstrated significant weight reduction in adults with obesity, regardless of type 2 diabetes (T2D) status. Findings from the phase 3 REDEFINE 1 and REDEFINE 2 trials were presented at the American Diabetes Association’s 85th Scientific Sessions in Chicago, June 2025.
REDEFINE 1 enrolled 3400 adults with obesity and at least one weight-related comorbidity (excluding diabetes). Participants were randomized to receive CagriSema 2.4 mg, semaglutide, cagrilintide, or placebo. After 68 weeks, those on CagriSema lost an average of 20.4% body weight, outperforming semaglutide (14.9%), cagrilintide (11.5%), and placebo (3.0%). Among fully adherent participants, average weight loss reached 22.7%, with 40.4% losing over 25%.
REDEFINE 2 evaluated 1200 adults with T2D. At week 68, CagriSema-treated patients lost 13.7% of body weight compared to 3.4% with placebo. Fully adherent individuals lost 15.7% vs 3.1%, respectively.
CagriSema’s safety profile was consistent with known GLP-1 receptor agonists, primarily causing mild-to-moderate gastrointestinal side effects. Researchers concluded that CagriSema significantly outperforms monotherapy and placebo for weight loss in both diabetic and non-diabetic populations, positioning it as a promising once-weekly option for obesity management.
